We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Role of maintenance chemotherapy in acute promyelocytic leukemia.
- Authors
Kantarjian, Hagop M.; Keating, Michael J.; Walters, Ronald S.; Smith, Terry L; McCredie, Kenneth B.; Freireich, Emil J; Kantarjian, H M; Keating, M J; Walters, R S; Smith, T L; McCredie, K B; Freireich, E J
- Abstract
The effect of maintenance chemotherapy on remission duration was analyzed in 39 of 70 patients (56%) with acute promyelocytic leukemia (APL) who achieved complete remission on induction chemotherapy. Overall, the median remission duration was 26 months, with a 3-year remission rate of 42%. The 3-year remission rate was significantly higher in patients who received 6-mercaptopurine and methotrexate (POMP) during maintenance, compared with those who did not (56% versus 30%; P less than 0.01), and in patients who received long-term maintenance therapy (P less than 0.01). A multivariate regression analysis selected maintenance therapy with POMP to be the only statistically significant factor associated with long-term remission duration. The type of maintenance chemotherapy is important in overall prognosis of patients with APL, and should be investigated further.
- Publication
Cancer (0008543X), 1987, Vol 59, Issue 7, p1258
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G